emerge glp-1 Journeys 1 journey with Side Effect Relief How GLP-1 medications are transforming

Graphical Abstract Similar content being viewed by others Introduction Obesity is an escalating global health issue

In April 2024, the FDA banned compounding pharmacies from producing versions of semaglutide (the active ingredient in medications like Ozempic and Wegovy)

The popularity of this class of medications, which includes Ozempic and Wegovy, is partly due to their widespread success for weight loss

Planning prevents that situation entirely

Glucagon-like peptide-1 receptor agonists during pregnancy and lactation

Not only is there a rapid weight gain for most patients, but there is documented re-worsening of comorbidities such as cardiovascular risk factors. The new insurance restrictions have fueled the use of direct-to-consumer programs such as NovoCare and LillyDirect, where prices range from $149 to $449 a month, depending on the drug and dosage